Dow Down0.25% Nasdaq Down0.26%

Sangamo Biosciences Inc. (SGMO)

14.05 0.43(3.00%) Aug 28, 4:00PM EDT
ProfileGet Profile for:
Sangamo Biosciences Inc.
501 Canal Boulevard
Richmond, CA 94804
United States - Map
Phone: 510-970-6000
Fax: 510-236-8951

Index Membership:N/A
Full Time Employees:85

Business Summary 

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The company’s principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimer’s disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntington’s disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Sangamo Biosciences Inc.

Corporate Governance 
Sangamo Biosciences Inc.’s ISS Governance QuickScore as of Aug 1, 2014 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 3; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Edward O. Lanphier II, 57
Founder, Chief Exec. Officer, Pres, Director and Member of Clinical Review Committee
Mr. H. Ward Wolff , 65
Chief Financial Officer, Principal Accounting Officer and Exec. VP
Dr. Geoffrey M. Nichol M.D., M.B.Ch.B., M.B.A., 59
Exec. VP of R&D
Dr. Philip D. Gregory D. Phil., 43
Chief Scientific Officer and Sr. VP of Research
Dr. Dale G. Ando M.D., 60
Chief Medical Officer and VP of Therapeutic Devel.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders